NCT03314064 - Phase 4 Study of Dolutegravir (DTG) in Russian Federation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 8, 2016

Primary Completion Date

October 1, 2018

Study Completion Date

October 1, 2018

Conditions

Infection, Human Immunodeficiency VirusHIV Infections

Interventions

DRUG

Dolutegravir 50 mg

DTG is an integrase inhibitor that has been developed for ART of HIV-infection in combination with other antiretrovirals. DTG will be available as 50 mg tablets to be administered once daily.

Trial Locations (11)

105275

GSK Investigational Site, Moscow

190103

GSK Investigational Site, Saint Petersburg

196645

GSK Investigational Site, Saint Petersburg

214006

GSK Investigational Site, Smolensk

302040

GSK Investigational Site, Oryol

350015

GSK Investigational Site, Krasnodar

420061

GSK Investigational Site, Kazan'

445846

GSK Investigational Site, Toliyatti

603005

GSK Investigational Site, N.Novgorod

620149

GSK Investigational Site, Yekaterinburg

650056

GSK Investigational Site, Kemerovo